Search Results 131-140 of 17323 for hba1c

  1. Measuring Glucagon Kinetics in Humans - Clinical Trials

    HbA1c ≤ 9% in T1DM subjects and < 5.7% in healthy nondiabetic subjects. normal fasting glucose (70-99 mg/dl) in healthy subjects; On insulin pump therapy ...

  2. A Study of the Effects of a Nocturnal Rise in Cortisol on Glucose Production in Type 2 Diabetes - Mayo Clinic

    ... HbA1c <10%; Subjects on thiazolidinediones may be included if they agree to stop these medications for at least 3-4 weeks before study visits; All women of ...

  3. A Study To Evaluate Setmelanoitide To Treat Patients With Rare Genetic Disorders Of Obesity - Mayo Clinic

    Any patient with a potentially clinically significant disease should be reviewed with the Sponsor to determine eligibility. HbA1c >9.0% at Screening ...

  4. Efficacy And Safety Of Treatment With Alpelisib Plus Endocrine Therapy In Patients With HR+, HER2-negative ABC, With PIK3CA Mutations, Whose Disease Has Progressed On Or After CDK 4/6 Treatment With An Aromatase Inhibitor (AI) Or Fulvestrant - Mayo Clinic

    ... (HbA1c) ≤ 6.4% (both criteria have to be met). *For patients with FPG ≥ 100 mg/dL and/or HbA1c ≥ 5.7% (i.e., threshold for pre-diabetes) at screening ...

  5. Study to Evaluate the Effects of Vitamin B3 Derivative on Bone, Skeletal, Muscle and Metabolic Functions in Aging - Mayo Clinic

    Poorly controlled Diabetes Mellitus (HbA1c>8). Clinical History Exclusion Criteria: Confirmed diagnosis of Diabetes Mellitus in use of insulin. Subjects ...

  6. Crossover Feasibility Study Of Portable AP Device With Zone-MPC And HMS And Adapted I:C And Basal Insulin - Mayo Clinic

    HbA1c ≤ to 10%, as measured with DCA2000 or equivalent device; Willing to perform the calibration of the study CGMs using a finger stick only and willing to ...

  7. Study Of BIIB092 In Participants With Progressive Supranuclear Palsy - Mayo Clinic

    Hemoglobin A1C (HbA1C) > 8%, confirmed by repeat. Allergies and Adverse Drug Reaction. History of allergy, hypersensitivity, or serious adverse reaction to ...

  8. Pemafibrate To Reduce Cardiovascular OutcoMes By Reducing Triglycerides IN PatiENts With DiabeTes (PROMINENT) - Mayo Clinic

    ... HbA1c (≥ 6.5% [48 mmol/mol]), elevated plasma glucose (fasting ≥ 126 mg/dL [7.0 mmol/L], 2-hour ≥ 200 mg/dL [11.1 mmol/L] during oral glucose tolerance ...

  9. Emricasan, A Caspase Inhibitor, For Evaluation In Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis - Mayo Clinic

    Uncontrolled diabetes (HbA1c ≥9%) within 60 days prior to day 1; Presence of cirrhosis on liver biopsy (fibrosis stage 4 based on the central ...

  10. A Study To Evaluate How Semaglutide Works Compared To Placebo In People With Type 2 Diabetes And Chronic Kidney Disease - Mayo Clinic

    Male or female, age above or equal to 18 years at the time of signing informed consent. · Diagnosed with type 2 diabetes mellitus. · HbA1c less than or equal to ...